JP2010507567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507567A5 JP2010507567A5 JP2009523960A JP2009523960A JP2010507567A5 JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5 JP 2009523960 A JP2009523960 A JP 2009523960A JP 2009523960 A JP2009523960 A JP 2009523960A JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutically acceptable
- cxcr4 inhibitor
- acceptable salt
- cxcr2 agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 10
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 8
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 5
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims 5
- 229960002169 plerixafor Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001483 mobilizing effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Claims (20)
- その動員を必要とする被験者の末梢血液内に前駆体または幹細胞あるいはその両方を動員するための、少なくとも一つのCXCR4阻害剤、少なくとも一つのCXCR2作動薬、およびG-CSFの有効量の使用。
- 末梢血液から動員された上記細胞の収穫をさらに含む、請求項1の使用。
- 生体外で収穫された上記細胞の培養をさらに含む、請求項2の使用。
- 収穫された上記細胞の被提供者である被験者への投与をさらに含む、請求項2の使用。
- 上記の被提供者である被験者が提供者である被験者と同一である、請求項4の使用。
- CXCR4阻害剤がAMD3100またはその薬学的に許容可能な塩である、請求項1の使用。
- CXCR2作動薬がGROβまたはその変形形態である、請求項1の使用。
- 少なくとも一つのCXCR4阻害剤、少なくとも一つのCXCR2作動薬、G-CSF及び薬学的に許容可能な賦形剤を活性成分として含有する医薬組成物。
- 被験者の末梢血液内に前駆細胞および／または幹細胞を動員するための、薬剤の製造における少なくとも一つのCXCR4阻害剤、少なくとも一つのCXCR2作動薬、およびG-CSFの有効量の使用。
- CXCR4阻害剤がAMD3100またはその薬学的に許容可能な塩である請求項9の使用。
- CXCR2作動薬がGROβまたはその変形形態である、請求項9または10の使用。
- 造血悪性腫瘍または骨髄性悪性腫瘍を患う被験者における化学療法または放射線療法の効果を高めるための、薬剤の製造における少なくとも一つのCXCR4阻害剤、少なくとも一つのCXCR2作動薬、およびG-CSFの有効量の使用。
- 腫瘍がリンパ腫、骨髄腫または白血病である、請求項12の使用。
- CXCR4阻害剤がAMD3100またはその薬学的に許容可能な塩である請求項12の使用。
- CXCR2作動薬がGROβまたはその変形形態である、請求項12または13の使用。
- CXCR4阻害剤がAMD3100またはその薬学的に許容可能な塩である請求項8の医薬組成物。
- CXCR2作動薬がGROβまたはその変形形態である、請求項8の医薬組成物。
- CXCR4阻害剤がAMD3456またはその薬学的に許容可能な塩である請求項1、9または12の使用。
- CXCR4阻害剤がAMD3456またはその薬学的に許容可能な塩である請求項8の医薬組成物。
- AMD3100またはその薬学的に許容可能な塩、GROβまたはその変形形態、G-CSF及び薬学的に許容可能な賦形剤を活性成分として含有する医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83640906P | 2006-08-07 | 2006-08-07 | |
| PCT/US2007/075376 WO2008019371A1 (en) | 2006-08-07 | 2007-08-07 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010507567A JP2010507567A (ja) | 2010-03-11 |
| JP2010507567A5 true JP2010507567A5 (ja) | 2010-09-30 |
Family
ID=39033325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523960A Withdrawn JP2010507567A (ja) | 2006-08-07 | 2007-08-07 | 併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100178271A1 (ja) |
| EP (1) | EP2056853A1 (ja) |
| JP (1) | JP2010507567A (ja) |
| CN (1) | CN101500595A (ja) |
| AR (1) | AR062271A1 (ja) |
| AU (1) | AU2007281677A1 (ja) |
| BR (1) | BRPI0715393A2 (ja) |
| CA (1) | CA2659337A1 (ja) |
| IL (1) | IL196559A0 (ja) |
| MX (1) | MX2009001445A (ja) |
| RU (1) | RU2009108289A (ja) |
| WO (1) | WO2008019371A1 (ja) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2675032A1 (en) * | 2007-01-09 | 2008-07-17 | Cleveland Biolabs, Inc. | Methods for increasing and mobilizing hematopoietic stem cells |
| EP2262494A2 (en) * | 2008-02-29 | 2010-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis |
| US20140219952A1 (en) | 2010-03-23 | 2014-08-07 | The Johns Hopkins University | Methods of treatment using stem cell mobilizers |
| US8546353B2 (en) | 2010-05-06 | 2013-10-01 | Glykos Finland Oy | Compounds and combinations |
| EP2384759A1 (en) | 2010-05-06 | 2011-11-09 | Suomen Punainen Risti Veripalvelu | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells |
| ES2370986B1 (es) * | 2010-06-08 | 2012-11-16 | Institut Quimic De Sarria Cets | Nuevos inhibidores de cxcr4 como agentes anti-vih |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
| US9682078B2 (en) | 2011-03-18 | 2017-06-20 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| US9763980B2 (en) | 2011-06-16 | 2017-09-19 | Children's Medical Center Corporation | Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| EP2961828A4 (en) * | 2013-02-28 | 2016-08-03 | Harvard College | COMPOSITIONS AND METHOD FOR MOBILIZING STEM CELLS |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10933049B2 (en) | 2015-06-03 | 2021-03-02 | The University Of Queensland | Mobilizing agents and uses therefor |
| WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| WO2018081181A1 (en) * | 2016-10-24 | 2018-05-03 | Yale University | Aspiration device |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| WO2019086597A1 (en) | 2017-11-03 | 2019-05-09 | Roemer & Heigl Gmbh | Extraction of stem cells from bone marrow niches |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
| MX2020005878A (es) * | 2017-12-06 | 2020-10-07 | Magenta Therapeutics Inc | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas. |
| EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| WO2022101359A1 (en) | 2020-11-12 | 2022-05-19 | Roemer & Heigl Gmbh | Reversible release of stem cells from bone marrow niches |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6447766B1 (en) * | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| DE69433301T2 (de) * | 1993-06-08 | 2004-09-09 | Smithkline Beecham Corp. | Methoden zur erhöhung der biologischen aktivität von chemokinen |
| DE4320478B4 (de) * | 1993-06-21 | 2007-11-15 | Robert Bosch Gmbh | Fahrstabilitätsregler |
| GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6713052B1 (en) * | 1995-10-24 | 2004-03-30 | Human Genome Sciences, Inc. | Method of mobilizing stem cells with chemokine β-8 |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| EP1244648B1 (en) * | 1999-12-17 | 2009-04-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds |
| NZ524651A (en) * | 2000-09-15 | 2005-08-26 | Anormed Inc | Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV |
| CA2419224A1 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| PL359292A1 (en) * | 2000-09-29 | 2004-08-23 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| US6853731B1 (en) * | 2000-09-30 | 2005-02-08 | Keen Personal Technologies, Inc. | Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device |
| WO2002081727A2 (en) * | 2001-04-03 | 2002-10-17 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| SI1411918T1 (sl) * | 2001-07-31 | 2012-04-30 | Genzyme Global S A R L | Postopki za mobilizacijo progenitorskih/matičnih celic |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| AU2002365796A1 (en) * | 2001-12-07 | 2003-06-17 | Toolgen, Inc. | Phenotypic screen of chimeric proteins |
| US7291631B2 (en) * | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
| CN101941964A (zh) * | 2003-04-22 | 2011-01-12 | 阿诺麦德股份有限公司 | 具有促进功效的趋化因子受体结合的杂环化合物 |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
-
2007
- 2007-08-07 CA CA002659337A patent/CA2659337A1/en not_active Abandoned
- 2007-08-07 BR BRPI0715393-7A patent/BRPI0715393A2/pt not_active Application Discontinuation
- 2007-08-07 EP EP07813853A patent/EP2056853A1/en active Pending
- 2007-08-07 AU AU2007281677A patent/AU2007281677A1/en not_active Abandoned
- 2007-08-07 US US12/376,591 patent/US20100178271A1/en not_active Abandoned
- 2007-08-07 MX MX2009001445A patent/MX2009001445A/es unknown
- 2007-08-07 WO PCT/US2007/075376 patent/WO2008019371A1/en active Application Filing
- 2007-08-07 AR ARP070103484A patent/AR062271A1/es unknown
- 2007-08-07 JP JP2009523960A patent/JP2010507567A/ja not_active Withdrawn
- 2007-08-07 CN CNA2007800295078A patent/CN101500595A/zh active Pending
- 2007-08-07 RU RU2009108289/15A patent/RU2009108289A/ru not_active Application Discontinuation
-
2009
- 2009-01-15 IL IL196559A patent/IL196559A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507567A5 (ja) | ||
| JP2009545620A5 (ja) | ||
| RU2009108289A (ru) | Комбинированная терапия | |
| Pusic et al. | Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells | |
| WO2018157171A3 (en) | Compositions, articles of manufacture and methods related to dosing in cell therapy | |
| JP2021059579A (ja) | 癌を処置するための医薬組合せ | |
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| JP2019503365A5 (ja) | ||
| JP2007529532A5 (ja) | ||
| MX2010010026A (es) | Agente para tratar enfermedad. | |
| JP2012067116A5 (ja) | ||
| JP2010501159A5 (ja) | ||
| CN106822905B (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
| JP2016517888A5 (ja) | ||
| NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| JP2013509429A5 (ja) | ||
| JP2009506054A5 (ja) | ||
| MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
| JP2009545600A5 (ja) | ||
| JP2011515481A5 (ja) | ||
| JP2023012503A5 (ja) | ||
| CO6771406A2 (es) | Una composición combinada | |
| US20150231198A1 (en) | Combination therapy for hematological malignancies | |
| MA56827B2 (fr) | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine |